Merkel Cell Polyomavirus-Pathophysiology and Treatment in the Era of Gene-Targeted Therapies

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor prognosis, strongly associated with Merkel cell polyomavirus (MCPyV).
• Current MCC treatments are often ineffective, particularly for metastatic disease, highlighting an urgent need for novel therapeutic strategies.
• MCPyV is a key factor in MCC development, though transmission routes and triggers require further elucidation.

Purpose of the Study:

• To provide a comprehensive review of MCPyV-positive MCC, encompassing its current understanding and the status of gene-targeted therapies.
• To discuss the significant challenges hindering MCC research and clinical translation of potential treatments.
• To explore future research prospects and therapeutic avenues for MCC.

Main Methods:

• Literature review synthesizing current knowledge on MCC pathogenesis and epidemiology.
• Analysis of preclinical and clinical data on gene-targeted therapies, including siRNA and CRISPR/Cas (C/Cas).
• Identification and discussion of obstacles in MCC research and clinical translation.

Main Results:

• MCPyV is a critical oncogenic driver in MCC, necessitating targeted therapeutic approaches.
• Gene-targeted therapies, such as siRNA and C/Cas, demonstrate significant preclinical potential for MCC treatment.
• Despite promising advancements, no gene-targeted therapies have reached clinical trials specifically for MCC.

Conclusions:

• Gene-targeted therapies represent a promising frontier for MCC treatment, building on existing successes of siRNA and C/Cas in other contexts.
• Overcoming research and clinical translation challenges is crucial for advancing MCC therapy.
• Further investigation into MCPyV-MCC biology and gene-editing technologies is essential for developing effective clinical strategies.